December 16, 2024
Biofidelity is proud to have been selected as a grant recipient by the Green Business Impact Programme, a collaborative effort led by Cambridge City Council, South Cambridgeshire District Council, Huntingdonshire District Council, the Cambridgeshire and Peterborough Growth Hub and the Cambridgeshire & Peterborough Combined Authority and administered by Allia Impact, Ltd.
December 03, 2024
Biofidelity announced the publication of data that highlights how Aspyre® technology addresses the urgent need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer.
November 21, 2024
Biofidelity today announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all guideline-recommended genes for non-small cell lung cancer (NSCLC) patients in both DNA and RNA from tissue and blood within two days, benefitting patients by enabling earlier treatment decisions.
April 12, 2024 Genomeweb
Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types with Aspyre Lung.
April 12, 2024 Cambridge Independent
Biofidelity’s successful $24 million financing round, which brings the total funding raised to $60m since being founded in 2019, will accelerate the growth of its game-changing Aspyre Lung genomic testing protocol.
April 05, 2024 Business North Carolina
Biofidelity, a genomic technology company with headquarters in the Research Triangle Park, has raised $24 million from investors in a new round of funding.
